These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 39164395)

  • 41. The neuromelanin of human substantia nigra: structure, synthesis and molecular behaviour.
    Zecca L; Zucca FA; Costi P; Tampellini D; Gatti A; Gerlach M; Riederer P; Fariello RG; Ito S; Gallorini M; Sulzer D
    J Neural Transm Suppl; 2003; (65):145-55. PubMed ID: 12946053
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Cell death and apoptosis regulating proteins in Parkinson's disease--a cautionary note.
    Wüllner U; Kornhuber J; Weller M; Schulz JB; Löschmann PA; Riederer P; Klockgether T
    Acta Neuropathol; 1999 Apr; 97(4):408-12. PubMed ID: 10208281
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Cell specific quantitative iron mapping on brain slices by immuno-µPIXE in healthy elderly and Parkinson's disease.
    Friedrich I; Reimann K; Jankuhn S; Kirilina E; Stieler J; Sonntag M; Meijer J; Weiskopf N; Reinert T; Arendt T; Morawski M
    Acta Neuropathol Commun; 2021 Mar; 9(1):47. PubMed ID: 33752749
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Why are nigral catecholaminergic neurons more vulnerable than other cells in Parkinson's disease?
    Hirsch EC
    Ann Neurol; 1992; 32 Suppl():S88-93. PubMed ID: 1510386
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Neuromelanin: Its role in the pathogenesis of idiopathic Parkinson's disease and potential as a therapeutic target.
    Mitra R; Premraj L; Khoo TK
    Parkinsonism Relat Disord; 2023 Jul; 112():105448. PubMed ID: 37236833
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Neuromelanin and Parkinson's disease.
    Marsden CD
    J Neural Transm Suppl; 1983; 19():121-41. PubMed ID: 6321645
    [TBL] [Abstract][Full Text] [Related]  

  • 47. In vivo reduction of age-dependent neuromelanin accumulation mitigates features of Parkinson's disease.
    Gonzalez-Sepulveda M; Compte J; Cuadros T; Nicolau A; Guillard-Sirieix C; Peñuelas N; Lorente-Picon M; Parent A; Romero-Giménez J; Cladera-Sastre JM; Laguna A; Vila M
    Brain; 2023 Mar; 146(3):1040-1052. PubMed ID: 36717986
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Neuromelanin can protect against iron-mediated oxidative damage in system modeling iron overload of brain aging and Parkinson's disease.
    Zecca L; Casella L; Albertini A; Bellei C; Zucca FA; Engelen M; Zadlo A; Szewczyk G; Zareba M; Sarna T
    J Neurochem; 2008 Aug; 106(4):1866-75. PubMed ID: 18624918
    [TBL] [Abstract][Full Text] [Related]  

  • 49. In vivo detection of iron and neuromelanin by transcranial sonography: a new approach for early detection of substantia nigra damage.
    Zecca L; Berg D; Arzberger T; Ruprecht P; Rausch WD; Musicco M; Tampellini D; Riederer P; Gerlach M; Becker G
    Mov Disord; 2005 Oct; 20(10):1278-85. PubMed ID: 15986424
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Iron in the basal ganglia in Parkinson's disease. An in vitro study using extended X-ray absorption fine structure and cryo-electron microscopy.
    Griffiths PD; Dobson BR; Jones GR; Clarke DT
    Brain; 1999 Apr; 122 ( Pt 4)():667-73. PubMed ID: 10219780
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Absolute quantification of neuromelanin in formalin-fixed human brains using absorbance spectrophotometry.
    Chand DA; Scadeng M; Dieriks BV
    PLoS One; 2023; 18(7):e0288327. PubMed ID: 37428719
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Alterations in the distribution of glutathione in the substantia nigra in Parkinson's disease.
    Pearce RK; Owen A; Daniel S; Jenner P; Marsden CD
    J Neural Transm (Vienna); 1997; 104(6-7):661-77. PubMed ID: 9444566
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Iron-melanin complex in substantia nigra of parkinsonian brains: an x-ray microanalysis.
    Jellinger K; Kienzl E; Rumpelmair G; Riederer P; Stachelberger H; Ben-Shachar D; Youdim MB
    J Neurochem; 1992 Sep; 59(3):1168-71. PubMed ID: 1494904
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Current views on the mechanisms of dopaminergic neuron death of the nigrostriatal system in Parkinson's disease].
    Bertrand E; Lechowicz W; Szpak GM; Dymecki J
    Neurol Neurochir Pol; 1997; 31(2):295-302. PubMed ID: 9380259
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Is Parkinson's disease a progressive siderosis of substantia nigra resulting in iron and melanin induced neurodegeneration?
    Youdim MB; Ben-Shachar D; Riederer P
    Acta Neurol Scand Suppl; 1989; 126():47-54. PubMed ID: 2618593
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Regional dopamine transporter gene expression in the substantia nigra from control and Parkinson's disease brains.
    Counihan TJ; Penney JB
    J Neurol Neurosurg Psychiatry; 1998 Aug; 65(2):164-9. PubMed ID: 9703165
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Neuromelanin of the substantia nigra: a neuronal black hole with protective and toxic characteristics.
    Zecca L; Zucca FA; Wilms H; Sulzer D
    Trends Neurosci; 2003 Nov; 26(11):578-80. PubMed ID: 14585596
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Disease duration and the integrity of the nigrostriatal system in Parkinson's disease.
    Kordower JH; Olanow CW; Dodiya HB; Chu Y; Beach TG; Adler CH; Halliday GM; Bartus RT
    Brain; 2013 Aug; 136(Pt 8):2419-31. PubMed ID: 23884810
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Modulation effect of substantia nigra iron deposition and functional connectivity on putamen glucose metabolism in Parkinson's disease.
    Zang Z; Song T; Li J; Yan S; Nie B; Mei S; Ma J; Yang Y; Shan B; Zhang Y; Lu J
    Hum Brain Mapp; 2022 Aug; 43(12):3735-3744. PubMed ID: 35471638
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Overexpression of alpha-synuclein in rat substantia nigra results in loss of dopaminergic neurons, phosphorylation of alpha-synuclein and activation of caspase-9: resemblance to pathogenetic changes in Parkinson's disease.
    Yamada M; Iwatsubo T; Mizuno Y; Mochizuki H
    J Neurochem; 2004 Oct; 91(2):451-61. PubMed ID: 15447678
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.